Physician profile
Donna K Ayers
NPI 1790836344
$2,465.16
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $754 · 2022: $1,043 · 2023: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $668.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $446.57 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $364.83 | 2021-2023 | Rexulti, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $328.16 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $301.91 | 2021-2023 | Austedo, Austedo Xr |
| Abbvie INC. | $301.08 | 2021-2023 | |
| Bausch Health US, LLC | $183.41 | 2021-2023 | Aplenzin, Wellbutrin |
| Alkermes, INC. | $171.38 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.65 | 2021-2023 | Trintellix |
| Idorsia Pharmaceuticals US INC | $55.07 | 2023 | Quviviq |
| Eisai INC. | $53.46 | 2021 | |
| Axsome Therapeutics, INC. | $39.34 | 2023 | Auvelity |
| Lundbeck LLC | $37.97 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $29.34 | 2022-2023 | Gardasil 9 |
| Jazz Pharmaceuticals INC. | $21.50 | 2022 | |
| Corium, LLC | $19.40 | 2023 | Azstarys |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $14.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Ayers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.